摘要
目的:研究清气化痰汤联合化疗对中晚期痰热蕴肺证非小细胞肺癌的临床疗效。方法:选取2022年1月至2022年12月在广西中医药大学第一附属医院肿瘤科就诊的90例符合研究标准的患者,采用随机数字分类形式分组,对照组实施化疗治疗,观察组实施清气化痰汤联合化疗治疗,对比两组血清肿瘤标志物、病症反应症候积分、不良反应发生率及临床疗效。结果:观察组血清肿瘤标志物:癌胚抗原(CEA)、糖类抗原125 (CA125)、细胞角蛋白19段(CYFRA21-1)指数较对照组降低(P < 0.05);观察组较对照组治疗后病症反应症候积分下降更为显著(P < 0.05);观察组不良反应发生率低于对照组(P < 0.05);观察组治疗有效率为95.56%,明显高于对照组57.78% (P < 0.05)。结论:运用清气化痰汤联合化疗治疗中晚期痰热蕴肺证非小细胞肺癌患者,可有效促进患者病症反应的缓解,减少不良反应的发生,改善血清肿瘤标志物指标,提高临床疗效。
Objective: To study the clinical effect of Qingqi Huatan Decoction combined with chemotherapy on middle and advanced non-small cell lung cancer with phlegm-heat accumulation syndrome. Methods: A total of 90 patients who met the criteria and were treated in the Oncology Department of the First Affiliated Hospital of Guangxi University of Chinese Medicine from January 2022 to December 2022 were selected and divided into groups by random number classification. The control group received chemotherapy treatment, and the observation group received Qingqi Huatan Decoction combined with chemotherapy treatment. Serum tumor markers, symptom scores, incidence of adverse reactions and clinical efficacy were compared between the two groups. Results: The serum tumor markers CEA, CA125 and CYFRA21-1 in observation group were lower than those in control group (P < 0.05). Symptom scores in observation group were significantly lower than those in control group after treatment (P < 0.05). The incidence of adverse reactions in observation group was lower than that in control group (P < 0.05). The effective rate of the observation group was 95.56%, which was significantly higher than that of the control group 57.78% (P < 0.05). Conclusion: Qingqi Huatan Decoction combined with chemotherapy in the treatment of middle and advanced non-small cell lung cancer patients with phlegm-heat accumulation syndrome can effectively promote the remission of disease reaction, reduce the occurrence of adverse reactions, improve serum tumor markers, and improve clinical efficacy.
出处
《中医学》
2024年第3期537-542,共6页
Traditional Chinese Medicine
